Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion has renewed speculation regarding potential mergers and acquisitions in the obesity drug sector, with Viking Therapeutics (VKTX) emerging as a target. Investor interest is heightened by ongoing developments in VKTX's clinical pipeline, particularly the VK2735 obesity drug and the newly launched VK3019 Phase 1 trial. Both drugs represent significant opportunities in a competitive market dominated by major players like Eli Lilly and Novo Nordisk. Key focal points for investors include the progress of VK2735 and VK3019 trials, potential synergies with acquirers, and the overall market landscape for obesity therapies.

Oops, something went wrong

Skip to navigation Skip to main content Skip to right column

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

Bailey Pemberton

Wed, July 8, 2026 at 5:12 AM EDT4 min read

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector.
Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target.
Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019.

Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital commitments from major biopharma companies. With both injectable and oral versions of VK2735 advancing, the company operates in a part of the market where larger players are actively seeking assets.

The launch of a Phase 1 trial for VK3019 adds another potential lever for future interest in Viking Therapeutics, beyond its flagship obesity programs. For investors tracking NasdaqCM:VKTX, the combination of active clinical work and ongoing M&A discussion is likely to keep news flow around the stock under close watch.

Stay updated on the most important news stories for Viking Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Viking Therapeutics.

NasdaqCM:VKTX Earnings & Revenue Growth as at Jul 2026

📰 Beyond the headline: 2 risks and 0 things going right for Viking Therapeutics that every investor should see.

For Viking Therapeutics, the renewed takeover talk following Vertex Pharmaceuticals' US$10b Crinetics deal comes at a time when its obesity franchise is already in the spotlight. VK2735 sits in late-stage VANQUISH trials with both injectable and planned oral formulations, while VK3019 is now in a Phase 1 single ascending dose study targeting the same broad obesity and metabolic disorders market. That combination gives potential acquirers a lead asset that is closer to commercial decision points, plus an earlier-stage program using a different hormone pathway, which could appeal to large pharma groups seeking diversified obesity portfolios similar to those of Eli Lilly and Novo Nordisk. At the same time, Viking is still a clinical-stage company with no approved products and relies on cash reserves and licensing arrangements to fund its pipeline. Takeover speculation can raise expectations, but any eventual deal terms, or the absence of a deal, are likely to be heavily influenced by the strength and safety profile of upcoming VK2735 and VK3019 data.

How This Fits Into The Viking Therapeutics Narrative

Story Continues

The progress of VK3019 into human testing and VK2735 into Phase 3 supports the existing narrative that Viking Therapeutics is building a focused obesity and metabolic disorder pipeline that could eventually address significant medical demand.
The renewed M&A attention highlights execution risk in the VANQUISH and oral VK2735 programs, because any delay, safety issue, or weaker than expected data would directly affect how attractive Viking appears to potential partners or acquirers.
The DACRA mechanism of VK3019 and its potential role alongside VK2735 may not be fully captured in earlier narratives that concentrated mainly on GLP-1 and GIP co-agonism and manufacturing scale up for VK2735.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Viking Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Viking Therapeutics remains a clinical-stage company with no revenue and ongoing losses, so it depends on cash reserves and potential future capital raises to fund VK2735, VK3019, and other programs.
⚠️ The obesity drug market is highly competitive, with established players such as Eli Lilly and Novo Nordisk already marketing GLP-1 based products, which may pressure future pricing power and market share if Viking's data or access terms are less compelling.
🎁 Concurrent development of injectable and oral VK2735, plus VK3019's dual amylin and calcitonin receptor approach, gives Viking a multi-asset obesity pipeline that could appeal to larger biopharma companies looking to expand in this therapy area.
🎁 The randomized, placebo-controlled design of the VK3019 Phase 1 trial, together with late-stage VANQUISH studies, provides a series of clear clinical milestones that investors can use to reassess risk and potential interest from would-be acquirers.

What To Watch Going Forward

From here, investors in Viking Therapeutics may want to track three areas closely. First, any updates on VANQUISH-1 and VANQUISH-2 timelines and safety or efficacy readouts for VK2735, since these Phase 3 programs remain the primary value drivers. Second, emerging data from the VK3019 Phase 1 trial, including safety, tolerability, and any early signals on weight and metabolic markers, which will help clarify whether it can be a meaningful follow-on asset. Third, any commentary from large pharmaceutical companies around their obesity acquisition priorities, as this may influence how realistic ongoing takeover speculation is and how much weight to give it in an investment thesis.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Viking Therapeutics, head to the community page for Viking Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VKTX .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com